Ascendiant Capital:维持60Degrees(SXTP.US)评级,由买入调整至买入评级,目标价由5.80美元调整至7.00美元。60Degrees Pharmaceuticals(SXTP.US)公司简介:60Degrees Pharmaceuticals Inc作为一家专业制药公司运营,目标是利用生物科学和应用研究来开发和商业化预防和治疗传染病的新疗法。该公司正在开发的产品线...
Source LinkAscendiant Capital:维持60Degrees(SXTP.US)评级,由买入调整至买入评级,目标价由5.80美元调整至7.00美元。60Degrees Pharmaceuticals(SXTP.US)公司简介:60Degrees Pharmaceuticals Inc作为一家专业制药公司运营,目标是利用生物科学和应用研究来开发和商业化预防和治疗传染病的新疗法。该公司正在开发的产品线...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.